Terguride Receives FDA Orphan Drug Designation For The Treatment Of Pulmonary Arterial Hypertension (Medical News Today)
Ergonex Pharma announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe.

(AFX UK Focus) 2008-05-15 09:14 India's Zydus Cadila gets 4 product approvals from U.S. FDA (Interactive Investor)
MUMBAI (Thomson Financial) - Indian pharmaceuticals company Zydus Cadila said it received four product approvals from the U.S. Food and Drug Administration with a market size of $6.498 billion.